{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:58:44Z","timestamp":1788346724456,"version":"build-2803163510"},"reference-count":99,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1053\/j.akdh.2024.02.004","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T16:02:07Z","timestamp":1720800127000},"page":"170-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Alport Syndrome"],"prefix":"10.1053","volume":"31","author":[{"given":"Efren","family":"Chavez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle N.","family":"Rheault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1313-7773","authenticated-orcid":false,"given":"Alessia","family":"Fornoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1053\/j.akdh.2024.02.004_bib1","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1056\/NEJMra022296","article-title":"Alport's syndrome, Goodpasture's syndrome, and type IV collagen","volume":"348","author":"Hudson","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.004_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2215\/CJN.04230321","article-title":"Guidelines for genetic testing and management of Alport syndrome","volume":"17","author":"Savige","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.akdh.2024.02.004_bib3","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1681\/ASN.2020071065","article-title":"Genomics England Research Consortium. Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome","volume":"32","author":"Gibson","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.004_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1806891","article-title":"Diagnostic utility of exome sequencing for kidney disease","volume":"380","author":"Groopman","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.004_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41431-022-01075-0","article-title":"The 2019 and 2021 International Workshops on Alport syndrome","volume":"30","author":"Daga","year":"2022","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.004_bib6","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.kint.2017.12.018","article-title":"Alport syndrome: a unified classification of genetic disorders of collagen IV \u03b1345: a position paper of the Alport syndrome classification working group","volume":"93","author":"Kashtan","year":"2018","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.akdh.2024.02.004_bib7","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2215\/CJN.03120322","article-title":"Digenic Alport syndrome","volume":"17","author":"Savige","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2024.02.004_bib8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/ndt\/gfv325","article-title":"Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis","volume":"31","author":"Gast","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.004_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2215\/CJN.08750718","article-title":"Integration of genetic testing and pathology for the diagnosis of adults with FSGS","volume":"14","author":"Yao","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.akdh.2024.02.004_bib10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ekir.2020.04.011","article-title":"Type IV collagen mutations in familial IgA nephropathy","volume":"5","author":"Li","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.004_bib11","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.ekir.2021.02.022","article-title":"Rare collagenous heterozygote variants in children with IgA nephropathy","volume":"6","author":"Cambier","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.004_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ekir.2019.09.004","article-title":"Collagen IV gene mutations in adults with Bilateral renal cysts and CKD","volume":"5","author":"Gulati","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.004_bib13","first-page":"33","article-title":"Glomerular filtration barrier assembly: an insight","volume":"1","author":"Arif","year":"2013","journal-title":"Postdoc J"},{"key":"10.1053\/j.akdh.2024.02.004_bib14","first-page":"130","article-title":"Extracelullar Matrix: Basement Membranes. In S.M. James& A. Williams (Eds.)","volume":"6","author":"Miner","year":"2022","journal-title":"Second Edition. Elsevier, London, UK"},{"issue":"15","key":"10.1053\/j.akdh.2024.02.004_bib15","doi-asserted-by":"crossref","first-page":"8767","DOI":"10.1074\/jbc.273.15.8767","article-title":"Glomerular basement membrane. Identification of a novel disulfide-cross-linked network of alpha3, alpha4, and alpha5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome","volume":"273","author":"Gunwar","year":"1998","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1053\/j.akdh.2024.02.004_bib16","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.kint.2020.06.038","article-title":"Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome","volume":"98","author":"Yamamura","year":"2020","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.akdh.2024.02.004_bib17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2215\/CJN.19171220","article-title":"Genetic Basis of type IV collagen disorders of the kidney","volume":"16","author":"Quinlan","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.004_bib18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ajkd.2020.03.026","article-title":"Alport syndrome: achieving early diagnosis and treatment","volume":"77","author":"Kashtan","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.akdh.2024.02.004_bib19","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1681\/ASN.V9122291","article-title":"High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.akdh.2024.02.004_bib20","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41431-021-00858-1","article-title":"Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria","volume":"29","author":"Savige","year":"2021","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.004_bib21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1053\/j.ajkd.2018.10.011","article-title":"Update on the native kidney biopsy: core curriculum 2019","volume":"73","author":"Luciano","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.004_bib22","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1053\/j.ajkd.2016.08.002","article-title":"AJKD Atlas of renal\u00a0pathology: Alport syndrome","volume":"68","author":"Fogo","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.004_bib23","first-page":"203","article-title":"Hereditary nephropathy (Alport syndrome): correlation of clinical data with glomerular basement membrane alterations","volume":"13","author":"Rumpelt","year":"1980","journal-title":"Clin Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.004_bib24","first-page":"276","article-title":"Alport syndrome and thin basement membrane nephropathy: diseases Arising from mutations in type IV collagen","volume":"14","author":"Kashtan","year":"2003","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1053\/j.akdh.2024.02.004_bib25","series-title":"Modern Surgical Pathology","first-page":"979","article-title":"Chapter 29. Non-neoplastic kidney","author":"Sabnis","year":"2009"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.004_bib26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s004670050471","article-title":"Renal biopsy diagnosis in children presenting with haematuria","volume":"12","author":"Piqueras","year":"1998","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.004_bib27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semnephrol.2005.01.006","article-title":"Pathology of thin basement membrane nephropathy","volume":"25","author":"Foster","year":"2005","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.akdh.2024.02.004_bib28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.matbio.2018.04.008","article-title":"Alport syndrome and Pierson syndrome: diseases of the glomerular basement membrane","volume":"71-72","author":"Funk","year":"2018","journal-title":"Matrix Biol"},{"issue":"9","key":"10.1053\/j.akdh.2024.02.004_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147253","article-title":"Loss of the collagen IV modifier prolyl 3-hydroxylase 2 causes thin basement membrane nephropathy","volume":"132","author":"Aypek","year":"2022","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1053\/j.akdh.2024.02.004_bib30","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/ndt\/gfl090","article-title":"Quantitative analysis of type IV collagen subchains in the glomerular basement membrane of patients with Alport syndrome with confocal microscopy","volume":"21","author":"Su","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.004_bib31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/ki.1996.316","article-title":"Relationship between COL4A5 gene mutation and distribution of type IV collagen in male X-linked Alport syndrome. Japanese Alport Network","volume":"50","author":"Naito","year":"1996","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.004_bib32","first-page":"986","article-title":"Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody","volume":"144","author":"Yoshioka","year":"1994","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.004_bib33","first-page":"116","article-title":"Skin biopsy for the diagnosis of Alport syndrome","volume":"12","author":"Lagona","year":"2008","journal-title":"Hippokratia"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.004_bib34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1681\/ASN.V114649","article-title":"X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males","volume":"11","author":"Jais","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.akdh.2024.02.004_bib35","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1097\/01.ASN.0000090034.71205.74","article-title":"X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a \"European Community Alport Syndrome Concerted Action\" study","volume":"14","author":"Jais","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.akdh.2024.02.004_bib36","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2215\/CJN.00580116","article-title":"Alport syndrome in women and girls","volume":"11","author":"Savige","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.akdh.2024.02.004_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161802","article-title":"X-linked and autosomal recessive Alport syndrome: pathogenic variant features and Further genotype-phenotype correlations","volume":"11","author":"Savige","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.004_bib38","first-page":"207","article-title":"X-linked, COL4A5 hypomorphic Alport mutations such as G624D and P628L may only exhibit thin basement membrane nephropathy with microhematuria and late onset kidney failure","volume":"17","author":"Pierides","year":"2013","journal-title":"Hippokratia"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.004_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm8020178","article-title":"Features of autosomal recessive Alport syndrome: a systematic review","volume":"8","author":"Lee","year":"2019","journal-title":"J Clin Med"},{"issue":"6","key":"10.1053\/j.akdh.2024.02.004_bib40","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/ckj\/sfz176","article-title":"Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review","volume":"13","author":"Matthaiou","year":"2020","journal-title":"Clin Kidney J"},{"issue":"9","key":"10.1053\/j.akdh.2024.02.004_bib41","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.ekir.2022.06.001","article-title":"Heterozygous pathogenic COL4A3 and COL4A4 variants (autosomal dominant Alport syndrome) are common, and not typically associated with end-stage kidney failure, hearing loss, or ocular abnormalities","volume":"7","author":"Savige","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.004_bib42","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/cge.13150","article-title":"Digenic inheritance and genetic modifiers","volume":"93","author":"Deltas","year":"2018","journal-title":"Clin Genet"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.004_bib43","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12882-018-0906-5","article-title":"COL4A5 and LAMA5 variants co-inherited in familial hematuria: digenic inheritance or genetic modifier effect?","volume":"19","author":"Voskarides","year":"2018","journal-title":"BMC Nephrol"},{"issue":"12","key":"10.1053\/j.akdh.2024.02.004_bib44","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/life10120360","article-title":"On Behalf of the Gpn study group, early Pro-Tect Alport investigators. Characterization of sensorineural hearing loss in children with Alport syndrome","volume":"10","author":"Boeckhaus","year":"2020","journal-title":"Life"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.004_bib45","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00467-020-04819-6","article-title":"Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020","volume":"36","author":"Kashtan","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"10.1053\/j.akdh.2024.02.004_bib46","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2215\/CJN.01000116","article-title":"Genetic, clinical, and pathologic backgrounds of patients with autosomal dominant Alport syndrome","volume":"11","author":"Kamiyoshi","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.004_bib47","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/ndt\/gfn681","article-title":"Autosomal dominant Alport syndrome: molecular analysis of the COL4A4 gene and clinical outcome","volume":"24","author":"Marcocci","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.004_bib48","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2215\/CJN.10581014","article-title":"Ocular features in Alport syndrome: pathogenesis and clinical significance","volume":"10","author":"Savige","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.akdh.2024.02.004_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.848389","article-title":"Novel therapies for Alport syndrome","volume":"9","author":"Chavez","year":"2022","journal-title":"Front Med"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.004_bib50","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.akdh.2024.02.004_bib51","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/ki.2011.452","article-title":"Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations","volume":"81","author":"Temme","year":"2012","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2024.02.004_bib52","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","volume":"97","author":"Gross","year":"2020","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.akdh.2024.02.004_bib53","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"10.1053\/j.akdh.2024.02.004_bib54","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMc1712572","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1053\/j.akdh.2024.02.004_bib55","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"DAPA-CKD trial Committees and investigators. Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.004_bib56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.akdh.2024.02.004_bib57","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"CREDENCE trial investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.akdh.2024.02.004_bib58","first-page":"1094","article-title":"Empagliflozin, cardiovascular outcomes, and Mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1053\/j.akdh.2024.02.004_bib59","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"EMPEROR-reduced trial investigators. Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1053\/j.akdh.2024.02.004_bib60","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"EMPEROR-preserved trial investigators. Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.004_bib61","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1053\/j.akdh.2024.02.004_bib62","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.83353","article-title":"Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome","volume":"12","author":"Ge","year":"2023","journal-title":"Elife"},{"issue":"15","key":"10.1053\/j.akdh.2024.02.004_bib63","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.004_bib64","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/s41598-019-41253-7","article-title":"Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: a possible role of SGLT2 in mesangial cells","volume":"9","author":"Maki","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.004_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151585","article-title":"Sodium glucose cotransporter 2 (SGLT2) Plays as a physiological glucose sensor and regulates cellular contractility in Rat mesangial cells","volume":"11","author":"Wakisaka","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.004_bib66","doi-asserted-by":"crossref","first-page":"C464","DOI":"10.1152\/ajpcell.00563.2009","article-title":"Bioenergetic characterization of mouse podocytes","volume":"299","author":"Abe","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.004_bib67","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","article-title":"Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development","volume":"21","author":"Kang","year":"2015","journal-title":"Nat Med"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.004_bib68","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"issue":"9","key":"10.1053\/j.akdh.2024.02.004_bib69","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.ekir.2022.06.017","article-title":"Efficacy of dapagliflozin in adult autosomal recessive Alport syndrome","volume":"7","author":"Song","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.004_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2021.11.007","article-title":"Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: an extraordinary paradigm shift","volume":"12","author":"Epstein","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.004_bib71","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.kisu.2021.11.004","article-title":"Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease","volume":"12","author":"Nakamura","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.004_bib72","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.akdh.2024.02.004_bib73","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2024.02.004_bib74","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","article-title":"Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review","volume":"25","author":"Mavrakanas","year":"2014","journal-title":"Eur J Intern Med"},{"issue":"23","key":"10.1053\/j.akdh.2024.02.004_bib75","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.004_bib78","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.3390\/ijms24043427","article-title":"Endothelin receptor antagonists in kidney disease","volume":"24","author":"Mart\u00ednez-D\u00edaz","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.004_bib79","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/path.6087","article-title":"Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice","volume":"260","author":"Cosgrove","year":"2023","journal-title":"J Pathol"},{"issue":"10184","key":"10.1053\/j.akdh.2024.02.004_bib81","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"SONAR Committees and Investigators. Atrasentan and renal events in patients with\u00a0type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.akdh.2024.02.004_bib83","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1194\/jlr.P040501","article-title":"Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy","volume":"55","author":"Herman-Edelstein","year":"2014","journal-title":"J Lipid Res"},{"issue":"11","key":"10.1053\/j.akdh.2024.02.004_bib84","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.2337\/db13-0399","article-title":"Cyclodextrin protects podocytes in diabetic kidney disease","volume":"62","author":"Merscher-Gomez","year":"2013","journal-title":"Diabetes"},{"issue":"9","key":"10.1053\/j.akdh.2024.02.004_bib85","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1172\/JCI85939","article-title":"Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury","volume":"126","author":"Pedigo","year":"2016","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1053\/j.akdh.2024.02.004_bib86","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.2337\/diabetes.54.8.2328","article-title":"Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb\/db mice with type 2 diabetes","volume":"54","author":"Wang","year":"2005","journal-title":"Diabetes"},{"issue":"8","key":"10.1053\/j.akdh.2024.02.004_bib87","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3390\/jpm11080820","article-title":"Use of lipid-modifying agents for the treatment of glomerular diseases","volume":"11","author":"Ge","year":"2021","journal-title":"J Pers Med"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.004_bib88","doi-asserted-by":"crossref","first-page":"755","DOI":"10.34067\/KID.0006152020","article-title":"Podocyte lipotoxicity in CKD","volume":"2","author":"Kim","year":"2021","journal-title":"Kidney360"},{"issue":"7","key":"10.1053\/j.akdh.2024.02.004_bib89","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrneph.2014.87","article-title":"Lipid biology of the podocyte--new perspectives offer new opportunities","volume":"10","author":"Fornoni","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.akdh.2024.02.004_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114465","article-title":"The role of lipotoxicity in kidney disease: from molecular mechanisms to therapeutic prospects","volume":"161","author":"Ren","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1053\/j.akdh.2024.02.004_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.00732","article-title":"The vicious cycle of renal lipotoxicity and mitochondrial dysfunction","volume":"11","author":"Ge","year":"2020","journal-title":"Front Physiol"},{"issue":"12","key":"10.1053\/j.akdh.2024.02.004_bib92","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-019-1263-x","article-title":"Crosstalk between lipids and Mitochondria in diabetic kidney disease","volume":"19","author":"Ducasa","year":"2019","journal-title":"Curr Diab Rep"},{"issue":"6","key":"10.1053\/j.akdh.2024.02.004_bib93","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.kint.2018.06.031","article-title":"Hydroxypropyl-\u03b2-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis","volume":"94","author":"Mitrofanova","year":"2018","journal-title":"Kidney Int"},{"key":"10.1053\/j.akdh.2024.02.004_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103162","article-title":"Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome","volume":"63","author":"Kim","year":"2021","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.004_bib95","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.kint.2020.06.040","article-title":"Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome","volume":"98","author":"Liu","year":"2020","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2024.02.004_bib96","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94818","article-title":"Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits","volume":"3","author":"Ding","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1053\/j.akdh.2024.02.004_bib97","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24890-3","article-title":"Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease","volume":"12","author":"Wright","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.004_bib99","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm0496-467","article-title":"Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations","volume":"2","author":"Howard","year":"1996","journal-title":"Nat Med"},{"issue":"8","key":"10.1053\/j.akdh.2024.02.004_bib100","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cpdd.914","article-title":"A randomized, double-blind, placebo-controlled, multiple Dose Escalation study to evaluate the safety and Pharmacokinetics of ELX-02 in healthy Subjects","volume":"10","author":"Leubitz","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"10.1053\/j.akdh.2024.02.004_bib102","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41431-019-0537-8","article-title":"New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells","volume":"28","author":"Daga","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"10.1053\/j.akdh.2024.02.004_bib103","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/sj.gt.3301342","article-title":"Adenovirus-mediated transfer of type IV collagen alpha5 chain cDNA into swine kidney in\u00a0vivo: deposition of the protein into the glomerular basement membrane","volume":"8","author":"Heikkil\u00e4","year":"2001","journal-title":"Gene Ther"},{"issue":"5","key":"10.1053\/j.akdh.2024.02.004_bib104","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/scd.2015.0305","article-title":"Human Chorionic stem cells: podocyte Differentiation and potential for the treatment of Alport syndrome","volume":"25","author":"Moschidou","year":"2016","journal-title":"Stem Cells Dev"},{"key":"10.1053\/j.akdh.2024.02.004_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.scr.2017.08.021","article-title":"Integration-free induced pluripotent stem cells derived from a patient with autosomal recessive Alport syndrome (ARAS)","volume":"25","author":"Kuebler","year":"2017","journal-title":"Stem Cell Res"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924000478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924000478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T14:59:54Z","timestamp":1728399594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813924000478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2949813924000478"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2024.02.004","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alport Syndrome","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2024.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}